| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NCPRHEUM0740 |
| P698 | PubMed publication ID | 18285765 |
| P2093 | author name string | Philip G de Groot | |
| Bas de Laat | |||
| Koen Mertens | |||
| P2860 | cites work | Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome | Q47225448 |
| A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants | Q47730463 | ||
| High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals | Q47900900 | ||
| A functional coagulation test to identify anti-beta2-glycoprotein I dependent lupus anticoagulants | Q49079388 | ||
| The binding site in {beta}2-glycoprotein I for ApoER2' on platelets is located in domain V. | Q51814798 | ||
| Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. | Q52574427 | ||
| Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. | Q53874974 | ||
| Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor | Q68090535 | ||
| Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease | Q68091809 | ||
| Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources | Q74253667 | ||
| The antiphospholipid syndrome | Q77739053 | ||
| The natural history of systemic lupus erythematosus: An approach to its study through chronic biologic false positive reactors | Q78586421 | ||
| Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay | Q80102029 | ||
| Antibody profiles for the diagnosis of antiphospholipid syndrome | Q81873167 | ||
| Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H) | Q24558202 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides | Q30676844 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation | Q33375186 | ||
| Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. | Q33504706 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Biologically false positive serologic tests for syphilis; type, incidence, and cause | Q34298183 | ||
| Viral infections and antiphospholipid antibodies | Q34522953 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome | Q35158386 | ||
| The clearance of apoptotic cells: implications for autoimmunity | Q35172149 | ||
| beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome | Q35829197 | ||
| Current concepts on the pathogenesis of the antiphospholipid syndrome | Q36598158 | ||
| Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. | Q36982870 | ||
| Platelets express three different splice variants of ApoER2 that are all involved in signaling | Q38302213 | ||
| Detection of anti-recombinant beta 2-glycoprotein 1 and anti-recombinant beta 2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus | Q38335330 | ||
| Pregnancy Loss in the Antiphospholipid-Antibody Syndrome — A Possible Thrombogenic Mechanism | Q41099260 | ||
| Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies | Q44241985 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis | Q45126748 | ||
| P433 | issue | 4 | |
| P921 | main subject | antibody | Q79460 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 192-199 | |
| P577 | publication date | 2008-02-19 | |
| P1433 | published in | Nature Clinical Practice Rheumatology | Q15752269 |
| P1476 | title | Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism | |
| P478 | volume | 4 |
| Q35250419 | "New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q39630876 | Antiphospholipid antibodies in dogs with immune mediated hemolytic anemia, spontaneous thrombosis, and hyperadrenocorticism |
| Q37378103 | Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes |
| Q38942818 | Aspirin-triggered lipoxin prevents antiphospholipid antibody effects on human trophoblast migration and endothelial cell interactions. |
| Q37228076 | Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study |
| Q34467454 | Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I |
| Q39044818 | Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function |
| Q33747286 | Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug |
| Q35419865 | Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I. |
| Q35927360 | Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy |
| Q37378113 | Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system |
| Q64092528 | New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats |
| Q38013583 | Obstetric and vascular APS: same autoantibodies but different diseases? |
| Q37704570 | Optimization of unnicked β2-glycoprotein I and high avidity anti-β2-glycoprotein I antibodies isolation |
| Q50943891 | Oxidatively altered IgG with increased immunoreactivity to β2-glycoprotein I and its peptide clusters influence human coronary artery endothelial cells. |
| Q37873720 | Pathogenesis of antiphospholipid syndrome: understanding the antibodies |
| Q37107290 | Pregnancy outcomes of antiphospholipid syndrome: In a low resource South Asian setting |
| Q38612651 | Prevention of Stroke in Rheumatoid Arthritis |
| Q33394629 | Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy |
| Q37577693 | Recent advances in understanding antiphospholipid syndrome. |
| Q37704593 | Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage |
| Q24316919 | Self-interaction of soluble and surface-bound beta2-glycoprotein I and its enhancement by lupus anticoagulants |
| Q36712941 | Taming lupus-a new understanding of pathogenesis is leading to clinical advances |
| Q37827404 | The clinical significance of coagulation and the inflammatory response in autoimmunity. |
| Q36890865 | Tracing the molecular pathogenesis of antiphospholipid syndrome |
| Q38970808 | Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast. |
Search more.